Immunotherapy for early-stage, resectable NSCLC

Prof. Heather Wakelee discusses the use of immune checkpoint inhibitors for early-stage, resectable NSCLC, considering the most recent data on pre-, post- and peri-operative immunotherapy and their impact on clinical practice.

The expert

• Prof. Heather A Wakelee – Stanford University, CA, USA

This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Merck & Co., Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
https://touchoncologyime.org/io-early-stage-nsclc/